Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07511816 · ClinicalTrials.gov registry record · Phase 2
A Study of LY4515100 in Participants With Pain Following Third Molar Removal
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT07511816 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 212 participants.
The verdict
NCT07511816, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.
Interventions
- DRUG Placebo
- DRUG LY4515100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07511816
The ClinicalTrials.gov registry entry for NCT07511816 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07511816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07511816 about?
NCT07511816 is a clinical study titled "A Study of LY4515100 in Participants With Pain Following Third Molar Removal". The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Res...
What is the current status of trial NCT07511816?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2026-04-01. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07511816?
The interventions under investigation include: Placebo (DRUG), LY4515100 (DRUG).
Who is sponsoring clinical trial NCT07511816?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.